BEAM vs VRTX
BEAM and VRTX side by side — valuation & fundamentals (public data).
Key statistics
| Metric | BEAMBeam Therapeutics Inc. | VRTXVERTEX PHARMACEUTICALS INC / MA |
|---|---|---|
| Market cap | $2.79B | $138.00B |
| P/E (TTM) | — | 31.7 |
| P/B | 2.93 | 6.82 |
| P/S | 20.0x | 11.4x |
| Revenue | $146.64M(TTM) | $12.59B(TTM) |
| Revenue growth (YoY) | 120.0% | 8.9% |
| Net income | -$108.35M(TTM) | $4.41B(TTM) |
| Earnings growth (YoY) | 78.8% | 838.1% |
| EPS, diluted | $-0.88(TTM) | $17.17(TTM) |
| EBIT margin | -274.6% | 34.8% |
| ROE | -8.4% | 19.5% |
| ROIC | -45.7% | 25.0% |
| 1y total return | +11.4% | +26.4% |
Figures from SEC filings · for reference only · not investment advice
Growth of $10,000: BEAM vs VRTX
| Metric | BEAM | VRTX |
|---|---|---|
| End value | $14.3K | $22.7K |
| Total return | +43.0% | +126.6% |
| CAGR | +5.5% | +12.9% |
| Volatility | 79.6% | 31.8% |
| Sharpe | 0.41 | 0.41 |
| Sortino | 0.63 | 0.56 |
| Max drawdown | -89.1% | -41.6% |
Based on 1695 common trading days, 2020-02-06 → 2026-11-03 · risk-free 4.21% (current short-Treasury, held constant)
A head-to-head total-return backtest over real split- and dividend-adjusted prices: how a one-time $10,000 investment in each stock, held to today, would have grown over their common window — including reinvested dividends. A disclosed historical statistic — NOT a prediction, a guarantee, or investment advice. Past performance does not predict future results.
Related comparisons
Delayed data · Public sources · For reference only · Not investment advice (this page declares no winner)